|
2010-01-06 |
2010-01-04 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.3%
19,24
3 848
USD
|
200
-1.3%
|
19,24
|
3 848
USD
|
|
|
2010-01-06 |
2010-01-04 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
19,08
1 908
USD
|
100
-0.6%
|
19,08
|
1 908
USD
|
|
|
2010-01-06 |
2010-01-04 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
95
-0.6%
19,14
1 818
USD
|
95
-0.6%
|
19,14
|
1 818
USD
|
|
|
2010-01-06 |
2010-01-04 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
5
-0.0%
19,17
96
USD
|
5
-0.0%
|
19,17
|
96
USD
|
|
|
2010-01-06 |
2010-01-04 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,84
1 884
USD
|
100
-0.6%
|
18,84
|
1 884
USD
|
|
|
2010-01-06 |
2010-01-04 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,78
1 878
USD
|
100
-0.6%
|
18,78
|
1 878
USD
|
|
|
2010-01-06 |
2010-01-04 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.6%
18,75
1 875
USD
|
100
-0.6%
|
18,75
|
1 875
USD
|
|
|
2009-10-07 |
2009-10-06 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
22,00
2 200
USD
|
100
-0.7%
|
22,00
|
2 200
USD
|
|
|
2009-10-07 |
2009-10-06 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
900
-6.1%
22,00
19 800
USD
|
900
-6.1%
|
22,00
|
19 800
USD
|
|
|
2009-09-22 |
2009-09-17 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
24,78
2 478
USD
|
100
-0.7%
|
24,78
|
2 478
USD
|
|
|
2009-09-22 |
2009-09-17 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
24,95
2 495
USD
|
100
-0.7%
|
24,95
|
2 495
USD
|
|
|
2009-09-22 |
2009-09-17 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
24,15
2 415
USD
|
100
-0.7%
|
24,15
|
2 415
USD
|
|
|
2009-09-22 |
2009-09-17 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
24,29
2 429
USD
|
100
-0.7%
|
24,29
|
2 429
USD
|
|
|
2009-09-22 |
2009-09-17 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
24,58
2 458
USD
|
100
-0.7%
|
24,58
|
2 458
USD
|
|
|
2009-09-22 |
2009-09-17 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
24,77
2 477
USD
|
100
-0.7%
|
24,77
|
2 477
USD
|
|
|
2009-09-22 |
2009-09-17 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
24,85
2 485
USD
|
100
-0.7%
|
24,85
|
2 485
USD
|
|
|
2009-09-22 |
2009-09-17 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
25,00
2 500
USD
|
100
-0.7%
|
25,00
|
2 500
USD
|
|
|
2009-09-22 |
2009-09-17 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.4%
24,47
4 894
USD
|
200
-1.4%
|
24,47
|
4 894
USD
|
|
|
2009-07-10 |
2009-07-10 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
400
+6.9%
18,95
7 580
USD
|
400
+6.9%
|
18,95
|
7 580
USD
|
|
|
2009-07-10 |
2009-07-10 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
300
+5.5%
18,96
5 688
USD
|
300
+5.5%
|
18,96
|
5 688
USD
|
|
|
2009-07-10 |
2009-07-10 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
1 600
+41.0%
19,00
30 400
USD
|
1 600
+41.0%
|
19,00
|
30 400
USD
|
|
|
2009-07-10 |
2009-07-10 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
1 000
+34.5%
19,02
19 020
USD
|
1 000
+34.5%
|
19,02
|
19 020
USD
|
|
|
2009-07-10 |
2009-07-10 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
200
+7.4%
19,03
3 806
USD
|
200
+7.4%
|
19,03
|
3 806
USD
|
|
|
2009-07-10 |
2009-07-10 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
300
+12.5%
19,04
5 712
USD
|
300
+12.5%
|
19,04
|
5 712
USD
|
|
|
2009-07-10 |
2009-07-10 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
700
+41.2%
19,05
13 335
USD
|
700
+41.2%
|
19,05
|
13 335
USD
|
|
|
2009-07-10 |
2009-07-10 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
500
+41.7%
19,08
9 540
USD
|
500
+41.7%
|
19,08
|
9 540
USD
|
|
|
2009-07-10 |
2009-07-08 |
A
Achat
|
Freund John Gordon
Administrateur non-exécutif
|
130 000
+12.3%
19,00
2 470 000
USD
|
130 000
+12.3%
|
19,00
|
2 470 000
USD
|
|
|
2009-07-02 |
2009-07-01 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
23,18
2 318
USD
|
100
-0.7%
|
23,18
|
2 318
USD
|
|
|
2009-07-02 |
2009-07-01 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
23,44
2 344
USD
|
100
-0.7%
|
23,44
|
2 344
USD
|
|
|
2009-07-02 |
2009-07-01 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
23,37
2 337
USD
|
100
-0.7%
|
23,37
|
2 337
USD
|
|
|
2009-07-02 |
2009-07-01 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.4%
23,28
4 656
USD
|
200
-1.4%
|
23,28
|
4 656
USD
|
|
|
2009-07-02 |
2009-07-01 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.4%
23,21
4 642
USD
|
200
-1.4%
|
23,21
|
4 642
USD
|
|
|
2009-07-02 |
2009-07-01 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
23,23
2 323
USD
|
100
-0.7%
|
23,23
|
2 323
USD
|
|
|
2009-07-02 |
2009-07-01 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
23,05
2 305
USD
|
100
-0.7%
|
23,05
|
2 305
USD
|
|
|
2009-07-02 |
2009-07-01 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
23,57
2 357
USD
|
100
-0.7%
|
23,57
|
2 357
USD
|
|
|
2009-06-15 |
2009-06-11 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
1 000
-6.8%
22,00
22 000
USD
|
1 000
-6.8%
|
22,00
|
22 000
USD
|
|
|
2009-03-26 |
2009-03-25 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
544
-4.0%
22,00
11 968
USD
|
544
-4.0%
|
22,00
|
11 968
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.8%
26,80
2 680
USD
|
100
-0.8%
|
26,80
|
2 680
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.8%
26,93
2 693
USD
|
100
-0.8%
|
26,93
|
2 693
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.8%
26,96
2 696
USD
|
100
-0.8%
|
26,96
|
2 696
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.8%
26,87
2 687
USD
|
100
-0.8%
|
26,87
|
2 687
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.8%
26,85
2 685
USD
|
100
-0.8%
|
26,85
|
2 685
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.5%
26,94
5 388
USD
|
200
-1.5%
|
26,94
|
5 388
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
27,12
2 712
USD
|
100
-0.7%
|
27,12
|
2 712
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,95
2 695
USD
|
100
-0.7%
|
26,95
|
2 695
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,92
2 692
USD
|
100
-0.7%
|
26,92
|
2 692
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,83
2 683
USD
|
100
-0.7%
|
26,83
|
2 683
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
200
-1.4%
26,79
5 358
USD
|
200
-1.4%
|
26,79
|
5 358
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
99
-0.7%
26,89
2 662
USD
|
99
-0.7%
|
26,89
|
2 662
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
1
-0.0%
26,91
27
USD
|
1
-0.0%
|
26,91
|
27
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,81
2 681
USD
|
100
-0.7%
|
26,81
|
2 681
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,75
2 675
USD
|
100
-0.7%
|
26,75
|
2 675
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,62
2 662
USD
|
100
-0.7%
|
26,62
|
2 662
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,49
2 649
USD
|
100
-0.7%
|
26,49
|
2 649
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,72
2 672
USD
|
100
-0.7%
|
26,72
|
2 672
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,64
2 664
USD
|
100
-0.7%
|
26,64
|
2 664
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,26
2 626
USD
|
100
-0.7%
|
26,26
|
2 626
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
27,10
2 710
USD
|
100
-0.7%
|
27,10
|
2 710
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,97
2 697
USD
|
100
-0.7%
|
26,97
|
2 697
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,87
2 687
USD
|
100
-0.7%
|
26,87
|
2 687
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,56
2 656
USD
|
100
-0.7%
|
26,56
|
2 656
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.7%
26,28
2 628
USD
|
100
-0.7%
|
26,28
|
2 628
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
29
-0.2%
26,67
773
USD
|
29
-0.2%
|
26,67
|
773
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
71
-0.5%
26,63
1 891
USD
|
71
-0.5%
|
26,63
|
1 891
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.8%
26,94
2 694
USD
|
100
-0.8%
|
26,94
|
2 694
USD
|
|
|
2009-02-03 |
2009-02-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.8%
27,01
2 701
USD
|
100
-0.8%
|
27,01
|
2 701
USD
|
|
|
2009-01-06 |
2009-01-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-1.0%
27,22
2 722
USD
|
100
-1.0%
|
27,22
|
2 722
USD
|
|
|
2009-01-06 |
2009-01-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-1.0%
27,00
2 700
USD
|
100
-1.0%
|
27,00
|
2 700
USD
|
|
|
2009-01-06 |
2009-01-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
8
-0.1%
26,53
212
USD
|
8
-0.1%
|
26,53
|
212
USD
|
|
|
2009-01-06 |
2009-01-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.9%
27,35
2 735
USD
|
100
-0.9%
|
27,35
|
2 735
USD
|
|
|
2009-01-06 |
2009-01-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.9%
26,97
2 697
USD
|
100
-0.9%
|
26,97
|
2 697
USD
|
|
|
2009-01-06 |
2009-01-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.9%
26,94
2 694
USD
|
100
-0.9%
|
26,94
|
2 694
USD
|
|
|
2009-01-06 |
2009-01-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.9%
26,10
2 610
USD
|
100
-0.9%
|
26,10
|
2 610
USD
|
|
|
2009-01-06 |
2009-01-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.9%
26,09
2 609
USD
|
100
-0.9%
|
26,09
|
2 609
USD
|
|
|
2009-01-06 |
2009-01-02 |
VP
Vente planifiée
|
Cundy Kenneth C
SVP, Preclinical Development
Dirigeant
|
100
-0.9%
26,18
2 618
USD
|
100
-0.9%
|
26,18
|
2 618
USD
|
|
